New drug may help keep esophageal cancer at bay after standard treatment

NCT ID NCT07246330

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just be observed. The study aims to see if toripalimab improves the time before the cancer progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab (a drug that helps the immune system fight cancer)
What this could lead to: If successful, this could provide a new treatment option to delay cancer progression in patients with advanced esophageal cancer.
What could go wrong: This is a Phase 3 trial, but results are not yet available. The drug may not improve outcomes for all patients and could cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.